[Drugs in oncology: an overview of benefit and refund practices in Europe]

Grössmann N, Wild C, Mayer J
Record ID 32016000989
Authors' objectives: This review provides an overview of all cancer drugs approved by the European Medicines Agency (EMA) between 2009 and 2015 and the state of knowledge on patient-benefit at the time of approval, and analyses which policies for high-prized cancer drugs are applied in other (European) countries.
Authors' recomendations: Assessments with (binding) recommendations, health economical evaluations, "Managed-Entry Agreements" and "Value-based pricing" are approaches to identify cancer drugs with the highest benefit whilst incurring acceptable costs, through transparent and traceable methods.
Project Status: Completed
Year Published: 2016
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Austria
MeSH Terms
  • Europe
  • Humans
  • Internal Medicine
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
Copyright: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.